You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)向裕利醫藥授予「思瑞康」馬來西亞及文萊獨家分銷權
阿思達克 08-02 11:24
綠葉製藥(02186.HK)公布,與裕利醫藥達成合作協議,將向其授予其中樞神經藥物「思瑞康」(富馬酸奎硫平,速釋)及「思瑞康緩釋片」(緩釋制劑)在馬來西亞和文萊兩國的獨家分銷權。

思瑞康及其緩釋片是具有抗抑鬱特性的非典型抗精神病藥物,用於治療精神分裂症和雙相情感障礙。綠葉製藥(國際)亞太區商務總監蕭幸偉表示,期望通過裕利醫藥的業務網絡和渠道優勢,提升思瑞康系列產品在該兩個市場的患者用藥可及性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account